Empify, LLC – Trademark Portfolio

Entity Type: 16

Empify, LLC holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 25 (Clothing) — 2 filings in this category. The portfolio also extends into Class 36 (Insurance & Financial) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include EMPIFY and WEALTH BUILDER EMPIFY EMPOWER MODIFY SALES PROFIT. The owner is based in Bala Cynwyd, PA.

150 Monument Road, Suite 207

Bala Cynwyd, PA 19004

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Empify, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

25
Clothing (2 filings)

Clothing, footwear, headgear

36
Insurance & Financial (2 filings)

Insurance; financial affairs; monetary affairs; real estate affairs

41
Education & Entertainment (1 filing)

Education; providing of training; entertainment; sporting and cultural activities

Frequently Asked Questions

How many trademarks does Empify, LLC have?

Empify, LLC has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned.

What trademark classes does Empify, LLC file in?

Empify, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 25 (Clothing), Class 36 (Insurance & Financial), Class 41 (Education & Entertainment). Class 25 covers clothing, footwear, headgear.

What are Empify, LLC's most well-known trademarks?

Empify, LLC's registered trademark portfolio includes well-known marks such as EMPIFY and WEALTH BUILDER EMPIFY EMPOWER MODIFY SALES PROFIT. These are among 2 currently registered trademarks in the portfolio.

What is Empify, LLC's trademark registration success rate?

Empify, LLC has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.